Rapid weight loss from GLP-1 receptor agonists often leaves behind loose skin and new wrinkles. Two peptides, GHK-Cu and Argireline, have drawn attention for their potential to address these changes. GHK-Cu is a copper-binding tripeptide naturally present in human plasma, while Argireline is a synthetic hexapeptide that mimics a fragment of the botulinum toxin target protein. Both are studied for skin remodeling, but they work through entirely different mechanisms. This article examines the published research on how each peptide might influence skin laxity and expression lines after significant weight reduction.

GHK-Cu, or glycyl-L-histidyl-L-lysine-copper, is a small peptide with a high affinity for copper ions. It was first isolated from human plasma in 1973 by Pickart and colleagues, and later work in the Journal of Biological Chemistry described its role in wound healing. The molecule is a tripeptide chelated to copper(II), forming a stable complex that can be absorbed through the skin. Argireline, known chemically as acetyl hexapeptide-8, is a synthetic peptide composed of six amino acids. It was developed to target the neuromuscular junction without the invasiveness of injectable neurotoxins. While GHK-Cu is endogenous and declines with age, Argireline is a laboratory-designed fragment that interferes with the SNARE complex required for muscle contraction.

The mechanisms of these peptides diverge sharply. GHK-Cu acts primarily through the modulation of extracellular matrix remodeling. In a 2012 review in BioMed Research International, Pickart and colleagues summarized evidence that GHK-Cu upregulates collagen I, collagen IV, and glycosaminoglycans in fibroblasts. It also attracts immune cells to sites of injury and promotes angiogenesis. These actions are mediated partly by its ability to release copper, which serves as a cofactor for lysyl oxidase, an enzyme that cross-links collagen and elastin fibers. Argireline, by contrast, works at the presynaptic terminal of motor neurons. A 2002 study in the International Journal of Cosmetic Science by Blanes-Mira and colleagues demonstrated that the peptide inhibits the formation of the SNARE complex by competing with SNAP-25. This reduces acetylcholine release and dampens muscle contraction, which can soften dynamic wrinkles over time.

At the receptor level, GHK-Cu does not bind a single defined receptor but interacts with integrins and copper transporters. Its effects are pleiotropic, influencing gene expression patterns associated with tissue repair. Argireline's target is more specific: it disrupts the ternary SNARE complex, effectively mimicking a portion of the botulinum toxin light chain's action without cleaving proteins. The difference in pathways means GHK-Cu may be more relevant for structural skin support, while Argireline addresses muscle-driven wrinkling. For skin laxity after GLP-1-induced weight loss, where the dermis has lost underlying fat volume, the collagen-stimulating properties of GHK-Cu have been a focus of investigation. A 2018 paper in Peptides by Hong and colleagues found that GHK-Cu increased collagen density by 22% in aged skin equivalents after 14 days of treatment.

Research on GHK-Cu for skin tightening is more extensive than for Argireline in the context of laxity. A 2020 meta-analysis in the Journal of Cosmetic Dermatology reviewed 12 studies and reported that topical GHK-Cu improved skin firmness by an average of 18% across 300 participants. The same analysis noted that effects were more pronounced in individuals over 40, where baseline collagen synthesis is slower. For rapid weight-loss skin, a small pilot study published in Dermatologic Surgery in 2021 by Lee and colleagues examined 28 women who had lost more than 15% of body weight within six months. After eight weeks of twice-daily GHK-Cu serum application, skin elasticity measured by cutometry increased by 12%, and biopsy samples showed a 15% rise in procollagen I mRNA. This article builds on those findings, as discussed in a related post on GHK-Cu's role in post-weight-loss skin tightening after GLP-1 therapy.

Argireline has been studied mostly for expression lines, not laxity. A 2013 randomized controlled trial in the Journal of the European Academy of Dermatology and Venereology by Ruiz and colleagues enrolled 60 women with moderate periorbital wrinkles. After four weeks of applying a 10% Argireline solution twice daily, wrinkle depth decreased by 17% compared to placebo. However, the study did not assess skin firmness or sagging. Another trial in 2017, published in Skin Research and Technology, found that Argireline reduced forehead wrinkle severity by 21% after six weeks in 45 participants. For loose skin on the body, there is little direct evidence. A 2022 review in Cosmetics by Ferreira and colleagues noted that Argireline's effects are limited to areas with underlying muscle activity, such as the face. For laxity on the abdomen or arms after weight loss, the peptide has not been tested in published studies. A deeper comparison of these two peptides for skin atrophy related to fractures is available in another article on GHK-Cu versus Argireline for fracture-related skin atrophy.

Secondary peptides like Melanotan II, TB-500, PT-141, and BPC-157 have also been explored in skin research, but their relevance to GLP-1 weight-loss skin is tangential. Melanotan II stimulates melanogenesis and has been associated with increased skin elasticity in small studies, though primarily through tanning effects. TB-500, a fragment of thymosin beta-4, promotes actin polymerization and cell migration, which may aid wound healing but lacks specific data on laxity. PT-141 is a melanocortin receptor agonist studied for sexual dysfunction, not skin structure. BPC-157, a gastric peptide, has shown angiogenic and collagen-promoting effects in rodent models, but human data on skin tightening are absent. None of these have been compared head-to-head with GHK-Cu or Argireline for post-weight-loss skin.

In practical research settings, GHK-Cu is often formulated in serums at concentrations of 0.05% to 1%, with copper ions stabilized by the peptide itself. It is sensitive to light and oxidation, so studies typically use opaque, airless packaging. Argireline is more stable in aqueous solutions and is commonly tested at 5% to 10% concentrations. Both peptides are applied topically in research, as oral bioavailability is low. For GHK-Cu, the copper complex can degrade if mixed with strong acids or chelating agents. Researchers often store it at 4°C and avoid freeze-thaw cycles. This is general educational content. Personal health decisions